You are here:

simeprevir (Olysio)

Advice

following a full submission

simeprevir (Olysio®) is accepted for use within NHS Scotland.

Indication under review: in combination with other medicinal products for the treatment of chronic hepatitis C in adult patients.

In four double-blind phase III studies, when given as part of triple regimen in combination with peginterferon-alfa and ribavirin, simeprevir was superior to placebo in treatment naive and prior relapsed patients and non-inferior to another direct acting antiviral drug  in treatment experienced patients with genotype 1 hepatitis C virus.

Drug Details

Drug Name: simeprevir (Olysio)
SMC Drug ID: 988/14
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with other medicinal products for the treatment of chronic hepatitis C in adult patients.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 13 October 2014

Back